However, one study has demonstrated that irinotecan-containing therapy improves PFS more than other treatment regimens in patients with pancreatic ductal adenocarcinoma harboring CHEK2/ATM mutations (germline/somatic) [28]. This evidence concerns the gene CHEK2 and pancreatic ductal adenocarcinoma.